Status and phase
Conditions
Treatments
About
The study objective was to evaluate the safety of ten consecutive days of therapeutic acetaminophen dosing in moderate alcohol consumers. The main outcome was liver injury (measured by an increase in mean serum ALT or AST levels). Patients were randomly assigned to 10 days of acetaminophen or placebo. Blood tests were measured at baseline, day 4 and day 11 to look for injury. We hypothesized that there would be no difference in liver enzymes between the two groups.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion criteria Adult volunteers of age 21 years or older, regardless of ethnicity or gender, who provided written consent and met all three of the following criteria of a moderate alcohol consumer:
Exclusion Criteria
Subjects were excluded from the study at baseline if any of the following were evident at baseline:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal